Center for Applied Genomics and Precision Medicine, Duke University; Durham Veterans Affairs Medical Center; Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
Durham Veterans Affairs Medical Center.
Open Forum Infect Dis. 2016 Jan 19;3(1):ofw007. doi: 10.1093/ofid/ofw007. eCollection 2016 Jan.
Early, presymptomatic intervention with oseltamivir (corresponding to the onset of a published host-based genomic signature of influenza infection) resulted in decreased overall influenza symptoms (aggregate symptom scores of 23.5 vs 46.3), more rapid resolution of clinical disease (20 hours earlier), reduced viral shedding (total median tissue culture infectious dose [TCID50] 7.4 vs 9.7), and significantly reduced expression of several inflammatory cytokines (interferon-γ, tumor necrosis factor-α, interleukin-6, and others). The host genomic response to influenza infection is robust and may provide the means for early detection, more timely therapeutic interventions, a meaningful reduction in clinical disease, and an effective molecular means to track response to therapy.
早期、发病前使用奥司他韦（对应于流感感染的基于宿主的基因组特征的出现）干预可减少整体流感症状（综合症状评分从 23.5 降至 46.3），更迅速地缓解临床疾病（早 20 小时），减少病毒脱落（总中位数组织培养感染剂量 [TCID50] 从 7.4 降至 9.7），并显著降低几种炎症细胞因子（干扰素-γ、肿瘤坏死因子-α、白细胞介素-6 等）的表达。宿主对流感感染的基因组反应是强大的，可能为早期检测、更及时的治疗干预、显著减少临床疾病以及有效跟踪治疗反应提供分子手段。
